These data open a pathway to a therapeutic strategy for peripheral nerve injury, which may overcome the limitations of direct administration of exogenous BDNF or NGF, implicating miRNA-1 or let-7 targeting, correspondingly. The gene discussed is BDNF; the disease is peripheral nerve injury.